Participate in Research

Browse Clinical Trials
Alzheimer's Disease and Agitation Study
Protocol: STUDY00009374
Full Title
A Phase 2, Randomized, Double-blind, Three-Arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of orally administered BMS-986368, a FAAH/MGLL Inhibitor, for the treatment of Agitation in Participants with Alzheimer's Disease (BALANCE-AAD-1)
Description
Alzheimer’s disease (AD) affects memory, thinking, and behavior. Some people with AD can experience agitation. They might feel restless, cranky, or tense throughout the day.

There is no treatment for the agitation that people with AD experience. The University at Buffalo is studying if a new medicine can help to treat agitation in patients with AD.

Participants will be in the study for up to 22 weeks. They will complete the following:

-a screening period (1 visit within 4 weeks of starting treatment)
-a treatment period when they will take the study medicine (7 visits over 8 weeks)
-an optional extended treatment period (5 visits over 6 weeks)
-a safety follow-up period (3 visits over 4 weeks)

Participants will receive $100 - $125 for each visit. Caregivers will receive $100 for each visit.
Compensation: Yes
?
Compensation may include cash, checks, gift cards, debit cards, or incentives like gift baskets, technology items, or merchandise.
Eligibility
-Adults aged 55 to 90 years old
-Have been diagnosed with Alzheimer's Disease
-Have a history of experiencing agitation
Age Group: Adults
Principal Investigator: KINGA SZIGETI
ClinicalTrials.gov: Open Study
Contact(s)
Nicholas Audino
ncaudino@buffalo.edu

Want to Learn More?

Let us know how the study team can reach you. If you do not hear back within 2 business days, then reach out to the study team directly at the contact information above and someone will assist you.

Your information will be shared only with the research study team and administrative staff for recruitment and will remain confidential. Your information will be stored until study recruitment is closed. Should you no longer want this information to be provided in the aforementioned ways, please contact the study team directly.

Study teams can login to review submissions
Study Team Login